Drug company Actelion to pay $360M in kickback probe

BOSTON: A pharmaceutical company has agreed to pay $360 million to resolve allegations that it used a charitable foundation to pay kickbacks to Medicare patients.

The U.S. attorney’s office in Boston announced the settlement Thursday with Actelion Pharmaceuticals US Inc., which was acquired last year by health care giant Johnson & Johnson.

Federal prosecutors say South San Francisco-based Actelion illegally used a purportedly independent charity to cover the co-payments of thousands of Medicare patients taking its pulmonary arterial high blood pressure drugs.

Prosecutors say that helped the company convince patients to buy its drugs when the prices it set would have otherwise prevented them from doing so. The U.S. attorney’s office says that violated the anti-kickback law.

A message was left with Actelion on Thursday seeking comment.

  • Related Posts

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    AiMeD welcomes, also offering help design a Uniform National Framework for Holistic Transparency New Delhi/ Bangalore: Central government and Karnataka government have initiated measures to bring about greater transparency in…

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day